Associated Papers
MeCP2-driven chromatin organization controls nuclear stiffness.
Romero H et al.
Communications Biology, 2025
Interpreting the rich dialogue between astrocytes and neurons: An overview in Rett syndrome.
Postogna FM et al.
Brain Research Bulletin, 2025
MeCP2 ubiquitination and sumoylation, in search of a function†.
Kalani L et al.
Human Molecular Genetics, 2023
Unexpected thermodynamic signature for the interaction of hydroxymethylated DNA with MeCP2.
Ortega-Alarcon D et al.
International Journal of Biological Macromolecules, 2023
Mutations in the transcriptional regulator MeCP2 severely impact key cellular and molecular signatures of human astrocytes during maturation.
Sun J et al.
Cell Reports, 2023
Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage.
Collins BE et al.
Neuropsychiatric Disease and Treatment, 2022
Rett Syndrome: A Timely Review From Recognition to Current Clinical Approaches and Clinical Study Updates.
Ivy AS et al.
Seminars in Pediatric Neurology, 2021
Molecular Context-Dependent Effects Induced by Rett Syndrome-Associated Mutations in MeCP2.
Ortega-Alarcon D et al.
Biomolecules, 2020
The course of awake breathing disturbances across the lifespan in Rett syndrome.
Tarquinio DC et al.
Brain & Development, 2018
The intervening domain from MeCP2 enhances the DNA affinity of the methyl binding domain and provides an independent DNA interaction site.
Claveria-Gimeno R et al.
Scientific Reports, 2017
From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2.
Sheikh TI et al.
Scientific Reports, 2016
Binding Analysis of Methyl-CpG Binding Domain of MeCP2 and Rett Syndrome Mutations.
Yang Y et al.
Acs Chemical Biology, 2016
Visual evoked potentials detect cortical processing deficits in Rett syndrome.
LeBlanc JJ et al.
Annals of Neurology, 2015
Epigenetics, autism spectrum, and neurodevelopmental disorders.
Rangasamy S et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics, 2013
MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
Psoni S et al.
Brain & Development, 2012
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients.
Pini G et al.
Autism Research and Treatment, 2012
Epilepsy in Rett syndrome: association between phenotype and genotype, and implications for practice.
Cardoza B et al.
Seizure, 2011
F₄-neuroprostanes mediate neurological severity in Rett syndrome.
Signorini C et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2011
Epilepsy in Rett syndrome: clinical and genetic features.
Pintaudi M et al.
Epilepsy & Behavior : E&b, 2010
The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome.
Zeev BB et al.
Neurology, 2009
Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions.
Ghosh RP et al.
The Journal of Biological Chemistry, 2008
High levels of MeCP2 depress MHC class I expression in neuronal cells.
Miralvès J et al.
Plos One, 2007
The MECP2 gene mutation screening in Rett syndrome patients from Croatia.
Matijević T et al.
Annals of the New York Academy of Sciences, 2006
Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain.
Galvão TC et al.
Nucleic Acids Research, 2005